Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KAMRON LATIF SALEEM

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1295910099
CMS profile
331536
Location
LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$21.91

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $21.91 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $21.91 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KAMRON LATIF SALEEM

NPI 1295910099 · CMS profile ID 331536

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

LAS VEGAS, NV

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295910099?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KAMRON LATIF SALEEM, NPI 1295910099, CMS profile ID 331536. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295910099?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). KAMRON LATIF SALEEM, NPI 1295910099, CMS profile ID 331536. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295910099?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
KAMRON LATIF SALEEM, NPI 1295910099, CMS profile ID 331536, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1295910099?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $21.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $21.9111/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802110737 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12.13 1
PY2021 $21.91 1
PY2022 $513.34 23
PY2023 $413.23 15
PY2024 $316.10 14
PY2025 $384.81 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $151,287.81 82
PY2024 Principal investigator $41,824.31 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

82 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $8,055.00 12/29/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665164
Principal investigator 1 CSL Behring $463.00 12/18/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665136
Principal investigator 1 CSL Behring $463.00 12/18/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665138
Principal investigator 1 CSL Behring $75.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665108
Principal investigator 1 CSL Behring $164.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665110
Principal investigator 1 CSL Behring $300.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665112
Principal investigator 1 CSL Behring $615.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665114
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665120
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665122
Principal investigator 1 CSL Behring $169.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665124
Principal investigator 1 CSL Behring $408.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665126
Principal investigator 1 CSL Behring $408.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665128
Principal investigator 1 CSL Behring $463.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665130
Principal investigator 1 CSL Behring $710.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665132
Principal investigator 1 CSL Behring $7,916.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665134
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665160
Principal investigator 1 CSL Behring $82.00 12/05/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665162
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842441
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,432.00 12/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842443
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 12/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842950
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 12/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842952
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842958
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842960
Principal investigator 1 AKEBIA THERAPEUTICS INC $84.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842962
Principal investigator 1 AKEBIA THERAPEUTICS INC $354.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241842964
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843102
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843104
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843106
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 11/05/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843108
Principal investigator 1 CSL Behring $19,022.00 10/29/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665076
Principal investigator 1 CSL Behring $3,243.00 10/17/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665070
Principal investigator 1 CSL Behring $423.76 10/13/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665218
Principal investigator 1 CSL Behring $272.00 10/06/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665140
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 10/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843254
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 10/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843256
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 10/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843258
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 10/03/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843260
Principal investigator 1 CSL Behring $215.89 09/30/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665210
Principal investigator 1 CSL Behring $9,847.00 09/17/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665060
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 09/10/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843390
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 09/10/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843392
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 09/10/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843394
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 09/10/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843396
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 09/10/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843536
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 09/10/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843540
Principal investigator 1 CSL Behring $928.61 08/26/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665208
Principal investigator 1 CSL Behring $6,486.00 08/20/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665056
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843534
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843538
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 08/06/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843727
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 08/06/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843735
Principal investigator 1 CSL Behring $16.71 08/06/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665204
Principal investigator 1 CSL Behring $304.20 07/24/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665202
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843731
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241843739
Principal investigator 1 AKEBIA THERAPEUTICS INC $53.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844030
Principal investigator 1 AKEBIA THERAPEUTICS INC $222.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844034
Principal investigator 1 AKEBIA THERAPEUTICS INC $30.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844038
Principal investigator 1 AKEBIA THERAPEUTICS INC $126.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844042
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,767.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844045
Principal investigator 1 AKEBIA THERAPEUTICS INC $360.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844050
Principal investigator 1 AKEBIA THERAPEUTICS INC $3,480.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844054
Principal investigator 1 AKEBIA THERAPEUTICS INC $912.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844058
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,362.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844061
Principal investigator 1 AKEBIA THERAPEUTICS INC $759.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844064
Principal investigator 1 AKEBIA THERAPEUTICS INC $600.00 07/23/2025 Non-covered Recipient Entity
Kidney Specialists of Southern Nevada
A Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy of Three Times Weekly Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis No dispute reported 06/30/2026 1241844069
Principal investigator 1 CSL Behring $22,760.00 07/16/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665050
Principal investigator 1 CSL Behring $402.00 07/02/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665030
Principal investigator 1 CSL Behring $2,804.00 06/30/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665028
Principal investigator 1 CSL Behring $277.37 06/09/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665198
Principal investigator 1 CSL Behring $5,988.00 04/16/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665020
Principal investigator 1 CSL Behring $16.71 04/11/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665192
Principal investigator 1 CSL Behring $16.71 04/10/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665190
Principal investigator 1 CSL Behring $605.38 04/08/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665186
Principal investigator 1 CSL Behring $10,379.00 03/19/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665016
Principal investigator 1 CSL Behring $793.48 02/26/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665176
Principal investigator 1 CSL Behring $423.17 02/21/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665174
Principal investigator 1 CSL Behring $4,219.00 02/19/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665012
Principal investigator 1 CSL Behring $371.91 01/14/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665170
Principal investigator 1 CSL Behring $3,954.00 01/10/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665006
Principal investigator 1 CSL Behring $20,789.00 01/10/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665008
Principal investigator 1 CSL Behring $277.91 01/08/2025 Non-covered Recipient Entity
DaVita Clinical Research Nevada
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665166